Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)
Status:
Completed
Trial end date:
2022-12-02
Target enrollment:
Participant gender:
Summary
The purpose of the study is to learn about the safety, pharmacokinetics and antiviral
activity of the study medicine (RV299) for the potential treatment of respiratory syncytial
virus (RSV). RSV is a highly contagious virus that can lead to serious lung infections in
patients with reduced ability to fight infection. Most vulnerable populations include babies,
the elderly and patients that have received a bone marrow transplant.